Literature DB >> 7241304

Double elevator palsy.

H S Metz.   

Abstract

The majority of patients with monocular limitation of elevation probably have an inferior restriction as the cause of limited elevation. When there is no vertical deviation in the primary position, the absence of a superior rectus palsy is most likely. Treatment of cases with inferior restrictions consists of recession of the tight inferior rectus and conjunctival recession. If the vertical deviation in the primary position is large enough, inferior rectus recession may be combined with superior rectus resection. When superior rectus palsy is the cause of limited upgaze, transposition surgery, utilizing the lateral and medial rectus muscles transposed to the superior rectus insertion, can be utilized. This often results in significant correction of the vertical deviation in primary gaze, but only yields modest improvement of elevation. Restrictions, which may also be present, must first be released before transposition surgery can succeed. The evidence suggests that rarely need the mechanism of "double elevator palsy" be invoked to explain monocular limitation of elevation. When there is true weakness of elevation, superior rectus palsy alone can account for the clinical findings.

Entities:  

Mesh:

Year:  1981        PMID: 7241304     DOI: 10.3928/0191-3913-19810301-08

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN: 0191-3913            Impact factor:   1.402


  2 in total

1.  The role of thyroid eye disease and other factors in the overcorrection of hypotropia following unilateral adjustable suture recession of the inferior rectus (an American Ophthalmological Society thesis).

Authors:  Natalie C Kerr
Journal:  Trans Am Ophthalmol Soc       Date:  2011-12

2.  Vertical transposition of the horizontal recti (Knapp procedure) for the treatment of double elevator palsy: effectiveness and long-term stability.

Authors:  J P Burke; J B Ruben; W E Scott
Journal:  Br J Ophthalmol       Date:  1992-12       Impact factor: 4.638

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.